Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 12, 2008

Nektar Nixes 150 Employees

  • Nektar Therapeutics cut approximately 150 positions in an effort to transition from a drug delivery service provider to a therapeutics drug development organization. The company also reported that Hoyoung Huh, M.D., Ph.D., will step down from his position as COO and join BiPar Sciences as president and CEO. Dr. Huh will also serve on Nektar’s board of directors.

    “We are transforming Nektar into a world-class drug development company and these changes are a natural progression on the path to achieving this vision,” according to Howard W. Robin, president and CEO. “This restructuring aligns the organization with the future direction of our company and strengthens our ability to drive programs rapidly through the clinic.”

    Nektar is preserving the necessary technical and manufacturing personnel and capabilities to support its efforts to form a new partnership for its inhaled insulin programs.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.